07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

ColoVantage regulatory update

The New York State Department of Health approved Quest's blood-based ColoVantage colorectal cancer diagnostic. New York is the only state in the U.S. with an independent regulatory review process for laboratory developed tests. Quest said...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Quest Diagnostics sales and marketing update

Quest launched its blood-based ColoVantage colorectal cancer diagnostic in the U.S. The test is based on the methylated septin 9 (SEPT9) biomarker from Epigenomics AG (Xetra:ECX, Berlin, Germany). Quest has rights to SEPT9 under a...